TrumpRx and GLP-1 Drugs: What the Science Actually Says About the Weight-Loss Meds Now in the Political Spotlight
TrumpRx put semaglutide and tirzepatide on a government platform. Here's what the FDA labels and clinical trials say about how they work.
Here is the article, followed by the required JSON metadata block.
The White House just put GLP-1 weight-loss drugs on a government-run shopping platform — and a lot of people are asking the same question: what exactly are these medications, and do they actually work?
Reporting from CNBC described TrumpRx as a direct-to-consumer drug comparison site launched by the White House, and according to CBS News, a new weight-loss drug was added to the platform. Meanwhile, Fortune noted that TrumpRx "helps, though a bit less than advertised." And now the latest dispatch is zooming in specifically on the GLP-1 drugs listed there and how they work.
If you've been watching the news and wondering whether this affects you — here's what the science actually says.
What Is TrumpRx, Briefly?
TrumpRx is a White House-backed drug price comparison website. The administration positioned it as a way for Americans to find lower-cost prescription drugs, including weight-loss medications. According to ABC News, the site launched in early 2026. Separately, Healthcare Finance News reported that CMS officially launched a $50 price tag for weight-loss drugs in Medicare — a related but distinct policy move that has brought GLP-1 access into the mainstream conversation.
The key drugs in the spotlight are semaglutide (Wegovy) and tirzepatide (Zepbound). Here's what each one actually does.
How GLP-1 Drugs Work
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally releases after you eat. It signals your brain that you're full, slows how fast your stomach empties, and nudges your pancreas to release insulin.
MedlinePlus (NIH) describes weight as influenced by a complex interaction of biology, environment, and behavior — not simply willpower. GLP-1 receptor agonists tap into that biology directly.
Wegovy (semaglutide) is FDA-approved to reduce excess body weight long-term in adults with obesity, or adults with overweight who have at least one weight-related condition. According to the FDA's Wegovy label, it's also indicated to reduce the risk of major cardiovascular events — including heart attack and stroke — in adults with established cardiovascular disease and obesity or overweight.
Zepbound (tirzepatide) goes one step further. Per the FDA's Zepbound label, it activates both GIP and GLP-1 receptors — a dual mechanism that some researchers believe drives its particularly strong weight-loss results. It also holds an FDA indication for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
What the Clinical Trials Actually Showed
The results in peer-reviewed research are striking.
A 2024 study in Nature Medicine from the SELECT trial — one of the largest semaglutide outcome trials — examined long-term weight-loss effects in people with obesity but without diabetes. The researchers found sustained weight reduction over the trial period alongside cardiovascular benefit.
The STEP 4 trial, published in JAMA, found that continuing weekly semaglutide was significantly more effective than switching to placebo for maintaining weight loss — meaning stopping the drug tends to reverse the results.
On the tirzepatide side, the SURMOUNT-4 trial — also published in JAMA — showed that continued tirzepatide treatment maintained weight reduction in adults with obesity, reinforcing the same pattern: these drugs work best as ongoing therapy, not short-term fixes.
The Side Effects You Should Know About
Neither drug is without risk. The FDA's labels for both Wegovy and Zepbound list the same most common adverse reactions reported in clinical trials (occurring in 5% or more of patients): nausea, diarrhea, vomiting, constipation, and abdominal pain.
More serious warnings on Wegovy's label include acute pancreatitis, acute gallbladder disease, acute kidney injury, and a boxed warning about the risk of thyroid C-cell tumors seen in animal studies. The label also flags monitoring for suicidal behavior and ideation.
Zepbound's label carries similar warnings, and additionally notes the risk of pulmonary aspiration during general anesthesia — relevant if you're having surgery.
These are reported adverse reactions from clinical trials and post-marketing surveillance — not guarantees that you'll experience them. But they're worth knowing before you start a conversation with your prescriber.
The Access Question
The bigger story behind TrumpRx may be less about the drugs themselves and more about who can actually get them. KFF Health News reported that while some drug prices dropped under Trump administration actions, many others went up. And separately, KFF Health News also noted that a new Medicare option for weight-loss drugs is now available — though eligibility conditions apply.
MedlinePlus classifies obesity as a disease — defined as a BMI of 30 or higher — that raises the risk of type 2 diabetes, heart disease, kidney disease, and certain cancers. That framing matters for insurance and access arguments: treating obesity isn't cosmetic, it's medical.
What this means for you:
- TrumpRx lists GLP-1 weight-loss drugs — primarily semaglutide (Wegovy) and tirzepatide (Zepbound) — as part of a broader push to make prescription drugs more price-transparent for Americans.
- The clinical evidence is real: multiple large, peer-reviewed trials published in JAMA and Nature Medicine show meaningful weight loss with both drugs — but the effect largely reverses when you stop.
- Side effects are common and some are serious — the FDA labels for both drugs list GI symptoms as the most frequent complaints, with rarer but significant warnings around pancreatitis, gallbladder disease, and thyroid risk. Talk to your prescriber before starting either medication.
Not medical advice. Talk to your prescriber about your specific situation, eligibility, and any risks relevant to your health history.
